Page 4 - Sciences Co News Today

Exact Sciences Co. (NASDAQ:EXAS – Get Free Report) has been given a consensus rating of “Moderate Buy” by the fourteen analysts that are covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation and twelve have issued a buy recommendation on the company. The average twelve-month price objective among […]

Exact Sciences Co. (NASDAQ:EXAS – Get Free Report) General Counsel James Herriott sold 415 shares of the company’s stock in a transaction on Wednesday, February 21st. The shares were sold at an average price of $61.50, for a total transaction of $25,522.50. Following the completion of the sale, the general counsel now directly owns 6,943 […]

Exact Sciences Co. (NASDAQ:EXAS – Get Free Report) Director D Scott Coward sold 706 shares of the stock in a transaction on Wednesday, February 21st. The shares were sold at an average price of $61.50, for a total transaction of $43,419.00. Following the completion of the transaction, the director now directly owns 43,122 shares in […]

Exact Sciences Co. (NASDAQ:EXAS – Get Free Report) Director D Scott Coward sold 706 shares of the stock in a transaction that occurred on Wednesday, February 21st. The shares were sold at an average price of $61.50, for a total transaction of $43,419.00. Following the sale, the director now owns 43,122 shares in the company, […]

Exact Sciences Co. (NASDAQ:EXAS – Get Free Report) CFO Jeffrey Thomas Elliott sold 1,888 shares of the business’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $61.43, for a total value of $115,979.84. Following the completion of the transaction, the chief financial officer now […]

Exact Sciences Co. (NASDAQ:EXAS – Get Free Report) Director D Scott Coward sold 1,376 shares of the business’s stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $61.43, for a total value of $84,527.68. Following the completion of the transaction, the director now directly owns […]

Rhenman & Partners Asset Management AB trimmed its stake in Exact Sciences Co. (NASDAQ:EXAS – Free Report) by 8.6% in the third quarter, Holdings Channel.com reports. The firm owned 160,000 shares of the medical research company’s stock after selling 15,000 shares during the quarter. Rhenman & Partners Asset Management AB’s holdings in Exact Sciences were […]

Biondo Investment Advisors LLC increased its stake in shares of Exact Sciences Co. (NASDAQ:EXAS – Free Report) by 2.8% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 112,696 shares of the medical research company’s stock after buying an additional 3,103 shares […]

Biondo Investment Advisors LLC boosted its position in shares of Exact Sciences Co. (NASDAQ:EXAS – Free Report) by 2.8% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 112,696 shares of the medical research company’s stock after buying an additional 3,103 shares during the […]

Van ECK Associates Corp lowered its holdings in Exact Sciences Co. (NASDAQ:EXAS – Free Report) by 9.9% during the third quarter, HoldingsChannel.com reports. The fund owned 149,468 shares of the medical research company’s stock after selling 16,345 shares during the period. Van ECK Associates Corp’s holdings in Exact Sciences were worth $10,197,000 as of its […]